Last reviewed · How we verify
Condylox Topical Gel 0.5%
Podophyllotoxin arrests cell division by disrupting microtubule formation, causing necrosis of genital wart tissue.
Podophyllotoxin arrests cell division by disrupting microtubule formation, causing necrosis of genital wart tissue. Used for Genital warts (condylomata acuminata).
At a glance
| Generic name | Condylox Topical Gel 0.5% |
|---|---|
| Sponsor | Dermax SA |
| Drug class | Antimitotic agent |
| Target | Tubulin |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Podophyllotoxin is a lignan that binds to tubulin and prevents microtubule assembly, leading to mitotic arrest and cell death. When applied topically to genital warts (condylomata acuminata), it causes direct cytotoxic necrosis of the affected tissue. The drug is particularly effective against rapidly dividing cells characteristic of human papillomavirus (HPV)-induced warts.
Approved indications
- Genital warts (condylomata acuminata)
Common side effects
- Local irritation and erythema
- Burning or pain at application site
- Erosion or ulceration
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Condylox Topical Gel 0.5% CI brief — competitive landscape report
- Condylox Topical Gel 0.5% updates RSS · CI watch RSS
- Dermax SA portfolio CI